Invitrogen's Q3 Revenues Rise 11 Percent As Loss Swings to Profit | GenomeWeb
NEW YORK (GenomeWeb News) — Invitrogen late yesterday reported that third-quarter revenues rose 11 percent as R&D spending increased 9 percent and a net loss last year swung to a profit this time around.
 
Total receipts for the three months ended Sept. 30 rose to $315 million from $284.2 million year over year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.